To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Exact Sciences (EXAS) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” fourth-quarter 2025 investor letter. A copy of the same can be downloaded here. U.S. equity markets experienced a quarter shaped by optimism around potential monetary easing and caution related to economic growth and valuations. Early gains were driven by strong AI-related earnings and the US Federal Reserve’s rate cut in October. However, market sentiment cooled later in the quarter due to mixed signals from the Fed regardi ...

Group 1 - The article does not contain relevant content regarding company or industry insights [1]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Fred Alger Management, an investment management company, released its “Alger Small Cap Focus Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The US equity market ended the fourth quarter on a strong note, with the S&P surging 2.7%, maintaining its steady upward momentum. Investors' optimism was supported by better-than-expected corporate earnings, the US Federal Reserve’s further interest rate easing stance, and a resilient macroeconomic backdrop. Improving clarity on ...

NEW YORK  and NEW ORLEANS, Jan. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Exact Sciences Corporation (NasdaqCM: EXAS) to Abbott Laboratories (NYSE: ABT). Under the terms of the proposed transaction, shareholders of Exact Sciences will receive $105.00 in cash for each share of Exact Sciences that they own. KSF is seeking to determine whether this consideration and the proc ...

Group 1 - Narweena is an asset manager that focuses on identifying market dislocations due to poor understanding of long-term business prospects [1] - The firm aims to achieve excess risk-adjusted returns by targeting businesses with secular growth opportunities in markets with barriers to entry [1] - Narweena's investment strategy emphasizes company and industry fundamentals to uncover unique insights, with a high risk appetite and long-term investment horizon [1] Group 2 - The firm prefers smaller cap stocks and markets where competitive advantages are not immediately apparent [1] - Narweena believes that an aging population, low population growth, and stagnating productivity will create new investment opportunities distinct from historical trends [1] - Many industries may experience stagnation or secular decline, which could paradoxically enhance business performance due to reduced competition [1] Group 3 - Some businesses may face rising costs and diseconomies of scale, while economies are increasingly dominated by asset-light businesses [1] - The declining need for infrastructure investments is leading to a situation where a large pool of capital is pursuing a limited set of investment opportunities, driving up asset prices and compressing risk premia [1] - Richard Durant, the leader of Narweena, holds degrees in engineering and finance and an MBA, and has passed the CFA exams [1]

Group 1: Market Overview - As of January 2, 2026, two stocks in the health care sector are signaling potential warnings for momentum-focused investors [1] - The Relative Strength Index (RSI) is a key momentum indicator that helps traders assess stock performance by comparing price strength on up days versus down days [2] Group 2: Company Analysis - Teva Pharmaceutical Industries Ltd - Teva Pharmaceutical's long-term issuer credit rating was upgraded by S&P Global Ratings from 'BB' to 'BB+' with a stable outlook [6] - Teva's stock has increased approximately 16% over the past month, reaching a 52-week high of $31.99 [6] - The current RSI value for Teva is 71.6, indicating it may be overbought [6] - Teva's shares closed at $31.21, reflecting a slight decline of 0.4% [6] - Teva has a momentum score of 92.72 and a value score of 27.43 [6] Group 3: Company Analysis - Exact Sciences Corp - Exact Sciences was involved in a significant acquisition by Abbott Laboratories, which agreed to purchase the company for $105 per common share, totaling an equity value of approximately $21 billion [6] - Exact Sciences' stock has gained around 7% over the past month, with a 52-week high of $102.00 [6] - The RSI value for Exact Sciences is 77.8, suggesting it is also potentially overbought [6] - Exact Sciences' shares closed at $101.56, down 0.3% [6]

Group 1 - As of January 2, 2026, two stocks in the health care sector are identified as potential warnings for momentum-focused investors [1] - The Relative Strength Index (RSI) is a key momentum indicator, with values above 70 indicating that a stock may be overbought [2] - Teva Pharmaceutical Industries Ltd has an RSI value of 71.6, with a recent stock price of $31.21, reflecting a 16% gain over the past month [6] - Exact Sciences Corp has an RSI value of 77.8, with a recent stock price of $101.56, reflecting a 7% gain over the past month [6] Group 2 - Teva's long-term issuer credit rating was upgraded to 'BB+' from 'BB' by S&P Global Ratings, with a stable outlook [6] - Abbott Laboratories agreed to acquire Exact Sciences for $105 per common share, totaling approximately $21 billion in equity value [6] - Exact Sciences has an estimated enterprise value of $23 billion following the acquisition announcement [6]